SVRA is the ticker symbol for Savara Inc, a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks SVRA with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is SVRA a good stock to buy?

SVRA is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/SVRA.

Where does 13F Pro source SVRA data?

All Savara Inc fundamentals and ownership data come directly from SEC EDGAR. Savara Inc files with the SEC under CIK 1160308. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Savara Inc(SVRA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Savara Inc (SVRA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. SVRA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Savara Inc reports net income of $-40.2M, free cash flow of $-30.0M. Top institutional holders of SVRA by reported 13-F value include NEA Management Company, Bain Capital Life Sciences Investors, VR Adviser, based on the most recent SEC filings. SVRA trades on the Nasdaq exchange and files with the SEC under CIK 1160308. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SVRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Savara Inc directly from SEC EDGAR.

Net Income

$-40.2M

Free Cash Flow

$-30.0M

SVRA key financials by period

Savara Inc reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2020	10-K	$257.0K	$-49.6M	—
FY 2016	10-K	$400.0K	$-10.9M	—
FY 2015	10-K	$54.0K	$-9.0M	—
FY 2013	10-K	$2.1M	$-208.7M	—
FY 2012	10-K	$2.1M	$-187.2M	—
FY 2011	10-K	$2.1M	$-171.6M	—

Institutions holding SVRA

Institutional investors reporting a position in Savara Inc on SEC Form 13F.
Institution	Shares	Value	Reported
NEA Management Company	24,471,264	$150.7M	2026-06-30
Bain Capital Life Sciences Investors	17,600,621	$108.4M	2026-06-30
VR Adviser	14,745,943	$90.8M	2026-06-30
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	13,569,000	$83.6M	2026-06-30
BlackRock	12,494,498	$77.0M	2026-06-30
TCG Crossover Management	12,362,205	$76.2M	2026-06-30
Frazier Life Sciences Management, L.P.	9,720,852	$59.9M	2026-06-30
Polar Capital Plc	9,541,786	$58.8M	2026-06-30
VANGUARD CAPITAL MANAGEMENT	7,932,545	$48.9M	2026-06-30
Nantahala Capital Management	6,976,810	$43.0M	2026-06-30

SEC EDGAR: CIK 1160308 →

Savara Inc

SVRA

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.